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hallenging  CD30-positive  lymphomas  –  Current  challenges,  new
nsights  and  future  directions:  Joining  a  conversation  on  CD30+
ymphomas
hristian  Gisselbrechta,∗,  Peter  Borchmannb, Francesco  D’Amorec, Timothy  M.  Illidged,
ier Luigi  ZinzanieHôpital Saint-Louis, Paris, France
University Hospital of Cologne, Cologne, Germany
Aarhus University Hospital, Aarhus, Denmark
Manchester University, Manchester, UK
University of Bologna, Bologna, ItalyCD30 is a therapeutic target in the management of patients with
elapsed/refractory (R/R) Hodgkin lymphoma (HL) and systemic
naplastic large-cell lymphoma (sALCL). Brentuximab vedotin has
emonstrated efﬁcacy in the management of patients with R/R HL
nd sALCL, and may  potentially be relevant in the management of
ther CD30+ lymphomas. This webcast is of a satellite symposium
hat takes the form of a forum and serves as a platform for look-
ng at the latest clinical trials and exchanging information on the
aily management of CD30+ lymphomas. It includes several case
nd panel discussions, as well as some interactive dialogue with
he audience.
Discussions include current medical needs in the treatment of
D30+ haematological malignancies and current ongoing clinical
rial data (including efﬁcacy and safety) on novel treatment strate-
ies for patients with HL, sALCL, and peripheral T-cell lymphoma
PTCL). The selection of eligible patients and optimal management
f patients with R/R HL or sALCL receiving brentuximab vedotin
n daily practice are addressed, including patient eligibility, dos-
ng, optimal number of cycles, retreatment, and the management
f side effects. Ongoing clinical trials in the use of CD30-targeted
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in this webcast.
Complete footage of this webcast can be found here:
http://cd30lymphoma.elsevierresource.com/
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